Hong Kong stock announcement to uncover opportunities | SHOUCHENG intends to sell approximately 0.607 billion shares of SHOUGANG RES for about 1.4566 billion Hong Kong dollars.

IDREAMSKY (01119) has reached a collaboration with stc play in the fields of technology and gaming. ASCLETIS-B (01672): The weight loss candidate drug ASC47, which treats obesity, has shown better weight loss effects than single-agent semaglutide in preclinical models when used in combination.

Zhitong FinanceDec 18 10:06 ET

Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China

MT NewswiresDec 18 06:47 ET

REGENT PACIFIC (00575.HK) submitted a new drug application for Senstend to the National Medical Products Administration of China.

Gelonghui reported on December 18 that REGENT PACIFIC (00575.HK) announced that the company's strategic business partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. ("Jiangsu Wanbang Pharmaceutical", a wholly-owned subsidiary of Shanghai FOSUN PHARMA ("FOSUN")) submitted new drug application registration documents to the National Medical Products Administration on December 17, 2024, and approval is expected within 12 months from the submission date.

Gelonghui FinanceDec 18 05:15 ET

Express News | Regent Pacific Group Ltd - Submission of Senstend New Drug Application to Nmpa in China

ReutersDec 18 05:11 ET

REGENT PACIFIC: 2024 Interim Report

HKEXSep 23 04:33 ET · Announcements

REGENT PACIFIC: Unaudited Interim Results for the Six Months Ended 30 June 2024

HKEXAug 28 09:40 ET · Announcements